Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs NetFlix Inc (NFLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs NetFlix Inc — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while NetFlix Inc trades at $70.6 (market cap $293.39B). The key difference: NetFlix Inc is far larger — about 301.6× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, NetFlix Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and NetFlix Inc for 126 Days on average.
| MRVI | NFLX | |
|---|---|---|
Market Cap | $972.90M | $293.39B |
Volume | 4,325,710 | 27,708,338 |
Sector | Health | Media |
52-Week High | $9.00 | $124.13 |
52-Week Low | $2.83 | $67.06 |
Typical Hold Time | 0 Days | 126 Days |
Enterprise Value | $1.08B | $298.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Netflix (NFLX) trades at $70.61, up 0.44% with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.80, beating expectations, and maintains robust profitability with 28.22% net margin and 49.54% ROE. Recent news highlights content expansion into live sports and positive analyst sentiment with a $89.39 consensus price target.
Netflix presents a compelling growth story with expanding margins and strategic content investments, though technical indicators signal near-term caution. The stock offers 27% upside to analyst targets but faces competition and execution risks in live sports expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About NetFlix Inc
Netflix Inc. is an Internet subscription service for watching television shows and movies. Subscribers can instantly watch unlimited television shows and movies streamed over the Internet to their televisions, computers, and mobile devices and in the United States, subscribers can receive standard definition DVDs and Blu-ray Discs delivered to their homes.
Read more on NFLX →
